Oncology

A next-gen immunotherapy enters trials, hoping its safer design can unlock the immune system and form a potent combo against advanced solid tumors.

Beyond M&A, ACROBiosystems' bioSeedin summit redefines growth, connecting global capital with biotech innovation in a new era of strategic partnerships.

A new collaboration adapts world-class cancer treatment standards for Vietnam, offering new hope for women battling breast and ovarian cancer.

Ensem Therapeutics expands its global trial for ETX-636, a next-gen cancer drug designed to avoid common toxicities, into China's vast patient market.

A new platform, Accelerated Clinical Trials (ACT), promises to slash drug development timelines by up to 20 months, but faces regulatory and ethical hurdles.

With a major cash infusion, NeOnc Technologies is set to accelerate its promising therapies aimed at conquering the elusive blood-brain barrier.

With backing from a top hospital, VolitionRx seeks reimbursement for its Nu.Q® blood test, aiming to transform lung cancer care in France and beyond.

Following the departure of its R&D head, Immunocore streamlines leadership, betting on internal experts to drive its next wave of innovative therapies.

Quetzal Therapeutics’ oral capsule for a rare leukemia could replace grueling IVs. The FDA's Fast Track status signals a major shift for patients and investors.

With a Super Bowl ad, NFL icons like Rob Gronkowski and Novartis are demystifying prostate cancer screening to save lives. Relax, it's a blood test.

With new manufacturing deals, CS Diagnostics is set to enter the competitive global hygiene market, targeting infection control from hospitals to homes.

A new center in China is using a novel drug and special policies to offer hope against NUT carcinoma, a rare and deadly cancer affecting the young.

A new endowed $50,000 grant from a powerhouse partnership aims to accelerate cancer cures by supporting early-career scientists at a critical juncture.

A new partnership integrates whole-genome sequencing into a clinical trial for a novel cancer drug, promising to accelerate development and usher in a new era.

With promising brain scan data, a deep therapeutic pipeline, and a cash runway into 2027, Radiopharm Theranostics is gaining significant momentum.

A new collaboration with Multiply Labs aims to use advanced robotics to automate cell therapy production, potentially making these cures accessible to all.

Neurocrine Biosciences begins a Phase 2 trial for a new tardive dyskinesia drug, aiming to build on its market dominance and offer new hope for patients.

With fresh funding, Primmune is advancing its unique TLR7 agonist, designed for efficacy without severe side effects, into a pivotal melanoma trial in Australia.

Janux Therapeutics appoints Dr. William Go, a key leader behind YESCARTA®'s approval, as CMO to steer its novel immunotherapy pipeline through critical trials.

Following impressive Phase 2 results, Scancell's novel immunotherapy iSCIB1+ receives FDA clearance for a pivotal trial, offering new hope for patients.